Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-blind, Placebo- Controlled Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation

NCT06780930 is registered in ClinicalTrials.gov with Servier as lead sponsor.

NCT NCT06780930
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06780930 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo- Controlled Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation
Lead sponsor
Servier
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 18, 2024
Completion date
October 31, 2030
Enrollment
57 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

residual or recurrent grade 2 idh mutant glioma